News observation： China actively promotes multi-path COVID-19 drug research and development.

CCTV News:A few days ago, the reporter learned from the Ministry of Science and Technology that China has arranged COVID-19 drugs according to a number of technical routes, and formed a variety of key drugs, all of which have entered the clinical trial stage. Experts pointed out that vaccines and drugs are complementary "combination boxing" relationship. In the future, it is inseparable from prevention and control measures, vaccines and therapeutic drugs to fight the epidemic.

China has arranged COVID-19 drugs according to three technical routes: inhibiting virus replication, blocking virus from entering cells and regulating human immune system, and formed a variety of key drugs, all of which have entered the clinical trial stage.

According to experts, the three technical routes of drugs in COVID-19 have their own characteristics, and different strategies are adopted to "block" Covid-19’s infection in different physiological links. Take the inhibition of virus replication as an example. By making a "inferior" nucleotide to "cheat" the virus, making it use this "inferior" material in its own replication, directly blocking replication or making the virus "self-construction" a "unfinished project", virus replication can be successfully stopped. In addition, screening high-quality neutralizing antibodies is also a commonly used strategy. Through single-cell technology, the researchers found the "best soldier" to subdue Covid-19. Finding several kinds of neutralizing antibodies, combined with "cocktail therapy", will have a better therapeutic effect on the mutant strains in Covid-19.

According to statistics, at present, there are six kinds of COVID-19-specific drugs independently developed by China, and the two kinds of neutralizing antibody drugs, BRII-196 and BRII-198, are the fastest, which have been involved in the treatment of more than 700 patients in China. The R&D team has submitted the application materials for conditional listing to National Medical Products Administration on October 9, and it is expected to be approved for conditional listing before the end of December.

At the same time, the neutralizing antibody DXP604 has been used as a "sympathy drug" in beijing ditan hospital when patients have no other drugs available, and some patients have recovered after taking the drug.

After the outbreak of the COVID-19 epidemic, relevant enterprises, scientific research units and scientific and technological personnel in China continued to tackle key problems, and relevant departments cooperated in research and examination, actively promoted the research and development of multi-path drugs, quickly selected a variety of therapeutic drugs, and 31 drugs entered clinical trials, which played an important role in consolidating the achievements of epidemic prevention and control, effectively improving the cure rate and reducing the mortality rate.

Experts said that vaccines and drugs are complementary "combination boxing" relationship. In the future, it is inseparable from prevention and control measures, vaccines and therapeutic drugs to fight the epidemic. COVID-19’s therapeutic drugs, together with effective vaccines, are of great value to the formulation and revision of public policies for prevention and control in COVID-19. In the long run, the emergence of oral drugs has injected a "cardiotonic agent" into the world. With the cooperation of drugs, the pace of world opening and economic recovery will be accelerated.